Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset

Toyoaki Hida, Miyako Satouchi, Kazuhiko Nakagawa, Takashi Seto, Shingo Matsumoto, Katsuyuki Kiura, Hiroshi Nokihara, Haruyasu Murakami, Kota Tokushige, Ben Hatano, Makoto Nishio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset of Japanese patients with ALK-rearranged non-small cell lung cancer previously treated with platinum-based chemotherapy, who experienced disease progression on crizotinib. Methods: Patients with advanced ALK-rearranged non-small cell lung cancer, including those with asymptomatic or neurologically stable baseline brain metastases, received oral ceritinib 750 mg/day. Whole-body and intracranial responses were assessed by investigator and Blinded Independent Review Committee (RECIST v1.1). Safety and tolerability were also investigated. Results: All 24 Japanese patients had received ≥2 previous treatment regimens, with crizotinib the last therapy received prior to ceritinib. Median duration of ceritinib exposure was 8.1 (range: 0.2-12.5) months. Overall response rate was 45.8% (95% confidence interval: 25.6-67.2). Other efficacy endpoints included disease control rate (79.2% [95% confidence interval: 57.8-92.9]), time to response (median 1.9 months [range: 1.7-3.5]), duration of response (median 9.2 months [95% confidence interval: 4.0-not estimable]) and progression-free survival (median 6.6 months [95% confidence interval: 3.7-9.3]). Of the four patients with active baseline target brain lesions, two achieved an intracranial partial response (50%). The most commonly reported adverse events (majority grade 1/2) were nausea (91.7%), diarrhea (83.3%) and vomiting (83.3%).Conclusions: This study demonstrates the clinical activity and manageable tolerability of ceritinib in a Japanese subset of chemotherapy- and crizotinib-pretreated patients with ALK-rearranged non-small cell lung cancer who progressed on crizotinib, as was shown in the whole ASCEND-2 study population.

Original languageEnglish
Pages (from-to)618-624
Number of pages7
JournalJapanese journal of clinical oncology
Volume47
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Keywords

  • Clinical Trials
  • Interventional therapy
  • Lung medicine
  • Thoracic
  • Thoracic-others

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset'. Together they form a unique fingerprint.

  • Cite this

    Hida, T., Satouchi, M., Nakagawa, K., Seto, T., Matsumoto, S., Kiura, K., Nokihara, H., Murakami, H., Tokushige, K., Hatano, B., & Nishio, M. (2017). Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Japanese journal of clinical oncology, 47(7), 618-624. https://doi.org/10.1093/jjco/hyx045